SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999; 25: 584589.
  • 2
    Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–1982. Natl Cancer Inst Monogr. 1985; 68: 99112.
  • 3
    Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8: 855861.
  • 4
    Vaittinen P, Hemminki K. Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer. 2000; 88: 9981002.
  • 5
    Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000; 83: 384386.
  • 6
    Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population based study. Int J Radiat Oncol Biol Phys. 2003; 56: 10381045.
  • 7
    Kurtz JM, Amalric R, Brandone H, Ayme Y, Spitalier JM. Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation. Int J Radiat Oncol Biol Phys. 1998; 15: 277284.
  • 8
    Brenner H, Engelsmann B, Stegmaier C, Ziegler H. Clinical epidemiology of bilateral breast cancer. Cancer. 1993; 72: 36293635.
  • 9
    Gajalakshmi CK, Shanta V, Hakama M. Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol. 1998; 27: 743750.
  • 10
    Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993; 11: 15451552.
  • 11
    Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995; 13: 15781583.
  • 12
    Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark 1943–1980. Br J Cancer. 1986; 54: 483492.
  • 13
    Mariani L, Coradini D, Biganzoli E, et al. Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat. 1997; 44: 167178.
  • 14
    Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer. 1985; 55: 643647.
  • 15
    Fisher ER, Fisher B, Sass R, Wickerham L. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4): XI. Bilateral breast cancer. Cancer. 1984; 54: 30023011.
  • 16
    Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992; 136: 925936.
  • 17
    Loman N, Johansson O, Kristoffersson U, et al. Al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001; 93 16: 12151223.
  • 18
    Easton DF. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999; 91: 13101316.
  • 19
    Claus EB. Autosomal dominant inheritance of early onset breast cancer: implications for risk prediction. Cancer. 1994; 73: 643651.
  • 20
    Malander S, Ridderheim M, Masback A, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer. 2004; 40: 422428.
  • 21
    Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22: 23282335.
  • 22
    Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer. 1998; 34: 20002009.
  • 23
    Hislop TG, Elwood JM, Coldman AJ, Spinelli JJ, Worth A, Ellison LG. Second primary cancers of the breast: incidence and risk factors. Br J Cancer. 1984; 49: 7985.
  • 24
    Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol. 1988; 128: 309323.
  • 25
    Cook LS, White E, Schwartz SM, McKnight B, Daling JR, Weiss NS. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control. 1996; 7: 382390.
  • 26
    Eccles D, Simmonds P, Goddard J, et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer. 2001; 1: 6572.
  • 27
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 14511467.
  • 28
    Narod SA, Brunet J-S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet. 2000; 356: 18761881.
  • 29
    Buzdar AU, ATAC trialists' group. “Arimidex” (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer—efficacy overview. J Steroid Biochem Mol Biol. 2003; 86: 399403.
  • 30
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930942.